Deciphera to present data from DCC-3014 trial at CTOS annual meet
Category: #health  By Mateen Dalal  Date: 2019-11-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Deciphera to present data from DCC-3014 trial at CTOS annual meet
  • The ongoing clinical trial of DCC-3014 have shown preliminary anti-tumor activity. 
     
  • DCC-3014 validates emerging tolerability profile with no Grade 3 or Higher TEAEs.
     
  • Encore presentation of data from the INVICTUS Pivotal Phase 3 Study clinical trial will be presented in an oral presentation session.

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has reportedly announced the preliminary data from its Phase 1 clinical trial of DCC-3014, an oral inhibitor of CSF1R in patients who are suffering from diffuse-type TGCT (tenosynovial giant cell tumor), as well as encore representation of INVICTUS pivotal Phase 3 clinal trial of ripretinib, a broad-spectrum KIT/ PDGFRα inhibitor in patients who are suffering from advanced GIST (gastrointestinal stromal tumors).

Reportedly, results from these clinical trials will be presented at CTOS (Connective Tissue Oncology Society) annual meeting which will be held in Tokyo, Japan.  

According to Matthew L. Sherman, M.D., Chief Medical Officer and Executive Vice President of Deciphera, the company is thrilled to give out preliminary data from the initial TGCT patients who are registered in the ongoing Phase 1 study of DCC-3014. Even though, the TGCT program is in initial stages, Deciphera is encouraged by the evidence of anti-tumor activity along with emerging tolerability profile, he said.

Moreover, the company will register more TGCT patients to determine the potential of DCC-3014 to make an effective impact on the progression of disease and quality of life of patients, Sherman added.

Reportedly, Deciphera’s Phase 1 clinical trial of DCC-3014 was designed to determine the pharmacokinetics, pharmacodynamics, and safety of multiple doses of DCC-3014 in patients who are suffering from TGCT and solid tumors. 

Meanwhile, based on the positive INVICTUS data, the company expects to submit a new drug application to U.S. FDA for ripretinib for the treatment of patients who are suffering from advanced GIST in Q1 2020.

Source Credit - https://investors.deciphera.com/news-releases/news-release-details/deciphera-pharmaceuticals-inc-present-data-dcc-3014-and

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...